Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cellix has reported the worldwide launch of its VenaFlux platform, a semi-automated, high throughput microfluidic cell-based assay system, which measures cell adhesion to antibody-coated or endothelial- cell cultured microchannels, producing IC50 curves under shear stress conditions mimicking physiological flow.
Subscribe to our email newsletter
The system is said to offer scientists an important and unique tool for drug discovery. The VenaFlux is simple to use, reduces costly layers of animal model studies, and delivers specific, accurate, and reproducible results. Using the VenaFlux, scientists can rapidly obtain quantitative analyses and results for potential drug candidates in therapeutic areas including cardiovascular, respiratory, immunologic, autoimmune and oncologic disease states.
Vivienne Williams, CEO of Cellix, said: “Our VenaFlux accurately replicates cell behavior in human capillaries, an in vitro modeling system that has previously been difficult to achieve.”